Shares of Pulse Biosciences Inc. (NASDAQ: PLSE) surged 6.10% on October 30, 2024, following the company's release of its third-quarter 2024 financial results and a series of positive business updates.
The bioelectric medicine company reported a net loss of $12.7 million for the third quarter, but investors seemed to focus on the progress made in the development of its novel Nanosecond Pulsed Field Ablation (nsPFA) technology and the potential it holds across various applications.
One of the key highlights was the appointment of Dr. David Kenigsberg as Chief Medical Officer of Electrophysiology and the addition of Dr. Andrea Natale as a medical advisor. Both renowned physicians will contribute their expertise in supporting the clinical development of Pulse Biosciences' nano-PFA 360 Cardiac Catheter for the treatment of atrial fibrillation.
Furthermore, the company provided updates on the progress of clinical trials for its nsPFA technology. Pulse Biosciences expects to commence pivotal trials in the U.S. for its Percutaneous Electrode System for benign thyroid nodules, its Cardiac Surgical System for atrial fibrillation treatment, and its 360 Cardiac Catheter, all in mid-2025. These milestones are seen as crucial steps towards potential commercialization of the company's innovative technology.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。